Lexicon Pharmaceuticals (NASDAQ:LXRX) continues to see its pipeline winnowed down by clinical trial failures. A prospective drug for rheumatoid arthritis basically went away last year, and it was just about two months ago that the company announced that LX 1032 (telotristat etiprate) had failed to show significant efficacy in a Phase II study in ulcerative colitis. Now there's another piece of bad news to digest, as the company announced Tuesday morning that its Phase II study of LX 1033 in IBS-D (diarrhea-prominent irritable bowel syndrome) failed to meet its primary endpoint.
Lexicon may, or may not, go forward with another study of LX 1033 on the basis of post-hoc analysis that appears to suggest some efficacy. Either way,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|